Login
$HURA
$2.04 -$0.14 (6.42%) Close

Company Executives

$HURA Management Team

Dr. James Manuso

Independent Chairman of the Board

Age 76
Compensation $14.75K USD
Sex Male

Dr. James Bianco

Chief Executive Officer

Director

Age 68
Compensation $5.444M USD
Sex Male

Mr. Dan Dearborn

Chief Financial Officer

Age 58
Compensation $2.539M USD
Sex Male

Ms. Jenene Thomas

Investor Relations

Age -
Compensation -
Sex Female
Directors
6
serving now
Independent
4 of 6
stated in the proxy
Average tenure
Not stated
from year joined
CEO also chairs the board
No
James Manuso
Director Age On board Independent Committees Other public boards Pay Source
James Manuso
Not stated Not stated Independent
Audit Committee · Chair
None stated Not stated
Alan List
Not stated Not stated Independent None stated None stated Not stated
George Ng
Not stated Not stated Independent None stated None stated Not stated
Craig Tendler
Not stated Not stated Independent None stated None stated Not stated
James Bianco
Not stated Not stated Not independent None stated None stated Not stated
Robert E. Hoffman
Not stated Not stated Not independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

11 disclosed in the proxy filed Jul 9, 2026
Parkview Holdings One LLC
affiliate of K&V Investment, a holder of more than 5% of the fully diluted capital stock of the Company
$50 million

Loan Agreement under which Parkview agreed to extend a $50 million revolving credit facility maturing April 21, 2031, bearing 12% interest

With the Company Open in proxy
Parkview Holdings One LLC
affiliate of K&V Investment, a holder of more than 5% of the fully diluted capital stock of the Company
$5 million

Fee Letter providing a one-time commitment fee of $5 million paid by issuing 1,878,287 shares of common stock, subject to stockholder approval

With the Company Open in proxy
Parkview Holdings One LLC
affiliate of K&V Investment, a holder of more than 5% of the fully diluted capital stock of the Company
Amount not stated

Royalty Agreement granting Parkview an annual royalty on Net Sales of IFx-2.0 based products

With the Company Open in proxy
K&V Investment
Amount not stated

Warrant Amendment Agreements extending the exercise period of 4,364,873 warrants held by K&V Investment to April 21, 2031

With Parkview Open in proxy
Dr. Craig Tendler
director; owner of Tendler Biotech Consulting LLC
Hourly fee of $1,250
March 18, 2026 through April 30, 2026

Consulting Agreement for as-requested consulting services at an hourly fee of $1,250 plus expenses; no fees paid or accrued through April 30, 2026

With Tendler Biotech Consulting LLC Open in proxy
K&V Investment
$7 million
2025

December 2025 Securities Purchase Agreement and Side Letter for purchase of shares and Series A and Series B warrants at $1.95 per share in three closings

With the Company Open in proxy
Matthew Nachtrab Revocable Trust
holder of more than 5% of the fully diluted capital stock of the Company
$3.0 million
2025

Secured promissory note and loan agreement with loans up to $3.0 million, later amended to add warrants; loans repaid December 12, 2025

Pranabio Investments LLC and Garden Street House, LLC
affiliates of Samir Patel, beneficial owners of greater than 5% of the fully diluted capital stock
Approximately $3.7 million
2025

June 2025 offering in which Deferral Investors deferred purchase of a final tranche of shares and warrants, paid by December 31, 2025

With the Company Open in proxy
Pranabio Investments LLC, Garden Street House, LLC and Matthew Nachtrab
affiliates of Samir Patel and Matthew Nachtrab, beneficial owners of greater than 5% of the fully diluted capital stock
$3.2 million
2025

Final Purchase Agreements under which Deferral Investors bought $3.2 million of the final tranche in exchange for extending expiration of 2024 Warrants to December 31, 2030

With the Company Open in proxy
K&V Investment
holder of more than 5% of the fully diluted capital stock of the Company
$10.0 million
2024

Participation in Legacy TuHURA convertible note private placement via a $10.0 million subscription, converted into shares at the Kintara Merger, with a related warrant

With Legacy TuHURA Open in proxy
directors and executive officers
Amount not stated

Indemnification agreements with each director and executive officer covering liabilities arising from their service and advancement of expenses

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support